Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of switching to raltegravir and/or adding losartan on the inflammatory/immune-activation mediators in treated HIV patients

Trial Profile

Effect of switching to raltegravir and/or adding losartan on the inflammatory/immune-activation mediators in treated HIV patients

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Apr 2018

At a glance

  • Drugs Raltegravir (Primary) ; Losartan
  • Indications HIV-1 infections
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 19 Apr 2018 New trial record
    • 07 Mar 2018 Results presented at the 25th Conference on Retroviruses and Opportunistic Infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top